Guilin Feng1, Meijiao Lin2, Xiaolin Zhou3, Lihong Zhang4, Jing Li5, Jingfeng Ouyang6. 1. Gynecological Department of Traditional Chinese Medicine, School Clinic, Nanyang Normal University College, Nanyang 473000, China. 2. Department of Pediatrics, Dongzhimen Hospital Affialited to Beijing University of Chinese Medicine, Beijing 100700, China. 3. Department of Traditional Chinese Medicine, Nanyang Medical College, Nanyang 473061, China. 4. Department of Oncology, the Third People' Hospital of Zhengzhou City, Zhengzhou 465500, China. 5. Department of Traditional Chinese Medicine, Children' Hospital of Kaifeng, Henan province, 4750000,?China. 6. Morphology Laboratory, Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Abstract
OBJECTIVE: To assess the efficacy of Bushenjianpi prescription (BSJPP), a formula from Traditional Chinese Medicine, on a mouse model of autoimmune premature ovarian failure (POF) induced by mouse zona pellucida (ZP3) and to investigate the mechanisms underlying the action. METHODS: After randomization, POF was induced in the model mice by immunization with ZP3. One week later, mice received low (8.1 mg/kg), moderate (16.2 mg/kg) and high (32.4 mg/kg) doses of BSJPP by gastrogavage once daily for 90 days. Premarin (0.03 mg/kg) served as the positive group. Serum samples were collected 1 week after the last dose and stored at -20 for analysis. After cervical dislocation, the uterus and ovaries were collected aseptically for evaluation by histological assessment, scanning electron microscopy, immunohistochemical staining, and Western blot and reverse transcription-polymerase chain reaction analyses. RESULTS: Serum E2 levels in POF model mice were decreased, whereas follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were dramatically increased. Serum levels of E2, LH and FSH were reduced in POF model mice treated with BSJPP (moderate and high doses) and premarin. Anti-bone morphogenetic protein 15 (BMP-15) and connexin 43 (Cx43) were repressed in autoimmune POF model mice, whereas high expression was observed in control mice and those treated with BSJPP (moderate and high doses) and premarin. CONCLUSION: BSJPP is effective in treating ZP3-induced POF in mice and the increase in the expression of BMP-15 and Cx43 may be implicated in the mechanism underpinning the action.
OBJECTIVE: To assess the efficacy of Bushenjianpi prescription (BSJPP), a formula from Traditional Chinese Medicine, on a mouse model of autoimmune premature ovarian failure (POF) induced by mousezona pellucida (ZP3) and to investigate the mechanisms underlying the action. METHODS: After randomization, POF was induced in the model mice by immunization with ZP3. One week later, mice received low (8.1 mg/kg), moderate (16.2 mg/kg) and high (32.4 mg/kg) doses of BSJPP by gastrogavage once daily for 90 days. Premarin (0.03 mg/kg) served as the positive group. Serum samples were collected 1 week after the last dose and stored at -20 for analysis. After cervical dislocation, the uterus and ovaries were collected aseptically for evaluation by histological assessment, scanning electron microscopy, immunohistochemical staining, and Western blot and reverse transcription-polymerase chain reaction analyses. RESULTS: Serum E2 levels in POF model mice were decreased, whereas follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels were dramatically increased. Serum levels of E2, LH and FSH were reduced in POF model mice treated with BSJPP (moderate and high doses) and premarin. Anti-bone morphogenetic protein 15 (BMP-15) and connexin 43 (Cx43) were repressed in autoimmune POF model mice, whereas high expression was observed in control mice and those treated with BSJPP (moderate and high doses) and premarin. CONCLUSION:BSJPP is effective in treating ZP3-induced POF in mice and the increase in the expression of BMP-15 and Cx43 may be implicated in the mechanism underpinning the action.
Entities:
Keywords:
Chinese medical formula; Connexin 43; Follicle-stimulating hormone; Luteinizing hormone; Primary ovarian Insufficiency; Zona pellucida